News Related to Ras-mutated Metastatic Colorectal Cancer

Related coverage linked through entity extraction aliases.

Global Oncology Market Projected to Reach $748 Billion by 2035 on Immunotherapy Growth

Mar 03, 2026

The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.

Chemoimmunotherapy Advances in Anal and Colorectal Cancers Show Promise in First-Line Treatment

Feb 26, 2026

New combination therapies demonstrate improved outcomes in advanced anal and colorectal cancers, with retifanlimab plus chemotherapy approved for anal cancer and onvansertib showing strong efficacy signals in RAS-mutated colorectal cancer.